One of India’s leading pharmaceutical businesses, Sun Pharmaceutical Industries Ltd., makes specialized generic drugs worldwide. Many investors are intrigued by Sun Pharma future share price goals.
Sun Pharmaceutical Industries Ltd., located in Mumbai, India, trades as SUNPHARMA on the India National Stock Exchange. Sun Pharma, founded in 1983, is India’s biggest pharmaceutical firm in market valuation and revenue. Generic, over-the-counter, anti-retroviral, and API medications are its specialties.
Sun Pharma will grow steadily in 2024 as it expands globally and invests in R&D. Revenue should rise as the business prioritizes specialty drugs and sophisticated generics. We expect Sun Pharma’s share price to be between ₹1200 and ₹2,300 in 2024.
Year
Minimum Price (₹)
Maximum Price (₹)
2024
1200
2,300
Month
Minimum Price (₹)
Maximum Price (₹)
January
1200
1450
February
1400
1600
March
1500
1650
April
1400
1650
May
1450
1550
June
1450
1550
July
1550
1750
August
1700
1850
September
1800
1950
October
1850
2100
November
1950
2150
December
2100
2300
Sun Pharma share price Target 2025
Sun Pharma could profit from its robust product pipeline and growing penetration in developing countries in 2025. The company’s biosimilar and specialized product expenditures should pay off, raising share prices. We expect Sun Pharma’s share price to reach ₹2,000 to ₹2,800 in 2025.
Year
Minimum Price (₹)
Maximum Price (₹)
2025
2,000
2,800
Month
Minimum Price (₹)
Maximum Price (₹)
January
2,000
2,350
February
2,050
2,400
March
2,100
2,450
April
2,150
2,500
May
2,200
2,550
June
2,250
2,600
July
2,200
2,650
August
2,250
2,700
September
2,300
2,750
October
2,350
2,800
November
2,400
2,800
December
2,350
2,800
share price Target 2030
Sun Pharma to be a worldwide pharmaceutical leader by 2030. Long-term R&D, smart acquisitions, and high-value market emphasis could boost growth. We predict Sun Pharma share price to reach between ₹3,500 and ₹4,500 by 2030.
Year
Minimum Price (₹)
Maximum Price (₹)
2030
3,500
4,500
Month
Minimum Price (₹)
Maximum Price (₹)
January
3,500
3,600
February
3,550
3,650
March
3,600
3,700
April
3,650
3,750
May
3,700
3,800
June
3,750
3,850
July
3,800
3,900
August
3,850
3,950
September
3,900
4,000
October
3,950
4,100
November
4,000
4,300
December
4,200
4,500
Share Price Target 2050
Projecting 2050 share values requires conjecture owing to the lengthy time horizon. We can predict a range if Sun Pharma continues its growth track and reacts to market changes. Sun Pharma might become a worldwide pharmaceutical giant by 2050, with a share price between ₹10,000 and ₹15,000.
Year
Minimum Price (₹)
Maximum Price (₹)
2050
10,000
15,000
Month
Minimum Price (₹)
Maximum Price (₹)
January
10,000
10,500
February
10,200
10,700
March
10,400
10,900
April
10,600
11,100
May
10,800
11,300
June
11,000
11,500
July
11,200
11,700
August
11,400
11,900
September
11,600
12,100
October
11,800
12,500
November
12,000
13,000
December
12,500
15,000
Should I buy Sun Pharma stock?
Year
Minimum Price (₹)
Maximum Price (₹)
2024
1,200
2,300
2025
2,000
2,800
2030
3,500
4,500
2050
10,000
15,000
Many considerations must be considered while buying Sun Pharma shares. The company market position, product pipeline, and worldwide presence might boost growth. Investors should also consider regulatory issues, price concerns, and pharmaceutical industry competitiveness. Before investing, investigate and analyze your financial objectives.
Sun Pharma has consistently performed financially. Recent quarterly performance summary:
Quarter
Revenue (₹ Cr)
Net Profit (₹ Cr)
EPS (₹)
Q2 FY24
12,192
2,375
9.91
Q1 FY24
11,519
2,061
8.60
Q4 FY23
10,844
1,984
8.28
Q3 FY23
11,241
2,166
9.04
Expert forecasts on the future of Sun Pharmaceutical Industries Ltd.
Industry analysts are optimistic about Sun Pharma future. Many analysts expect the company specialist product emphasis, R&D spending, and developing market development to generate long-term growth. Important expert projections include:
Continued specialized expansion, especially dermatology and ophthalmology.
Market share growth in the US, India, and developing markets.
Cost reductions and product mix improvements may boost margins.
Patent cliffs for some branded medications provide biosimilar and complicated generic opportunities.
Possible strategic acquisitions to boost product and market share.
Is Sun Pharma stock good to buy? (bull case & bear case)
Bull Case:
Strong Indian market position and expanding worldwide exposure
Strong specialized and complicated generic pipeline
Continuous R&D investment for innovation and growth
Strong financial sheet, minimal debt
Operational efficiency and product mix may boost margins.
Regulatory concerns in important markets, including US FDA inspection
Increased generic drug competition causes price pressures
International revenue changes due to currency volatility
Depending on a few core goods for most revenue
Possible integration issues from future purchases
Conclusion
Sun Pharmaceutical Industries Ltd. is a worldwide pharmaceutical leader. With its strong market position, concentration on specialist goods, and smart R&D expenditures, the firm is poised for development. This article’s share price projections are based on current trends and expert analysis, but investors should remember that the stock market is unpredictable and vulnerable to internal and external influences. Before investing, you must study, assess your risk tolerance, and contact a financial expert.
FAQs
Sun Pharma develops, manufactures, and sells generic drugs and APIs.
Since 2020, Sun Pharma stock has appreciated due to its concentration on specialist goods and worldwide growth.
Specialty product expansion, emerging market market share increase, and complicated generics and biosimilar R&D are growth drivers.
Sun Pharma is India’s biggest pharmaceutical firm by market valuation and has a worldwide reach to rival its rivals.
Regulatory difficulties, generic medicine price pressures, currency changes, and acquisition integration concerns are major hazards.
